Moderna (NASDAQ: MRNA) — Perfil da empresa, notícias e dados financeiros
Moderna is a biotechnology company known for its mRNA technology, aiming to revolutionize vaccines and treatments.

Moderna
Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA medicines and vaccines. The company utilizes proprietary messenger RNA technology platforms to design therapeutics and preventive vaccines targeting infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular ailments. Its commercial portfolio includes preventive vaccines for viral respiratory pathogens alongside a pipeline of clinical candidates across multiple therapeutic areas. The company maintains biomanufacturing, research, and commercial operations internationally.
Resumo
Operações
Produtos e/ou serviços de Moderna
- Respiratory Vaccines: Commercial production and global supply of messenger RNA vaccines protecting against respiratory viral infections, including formulations for COVID-19 and respiratory syncytial virus administered across international healthcare markets.
- Infectious Disease Pipeline: Clinical development of investigational mRNA vaccines targeting latent and emerging pathogens, including cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and seasonal influenza strains.
- Immuno-Oncology Therapeutics: Advancement of individualized neoantigen therapies and off-the-shelf mRNA cancer vaccines designed to stimulate targeted T-cell immune responses against specific tumor antigens in combination with checkpoint inhibitors.
- Rare Disease Therapies: Development of systemic messenger RNA therapeutics designed to instruct human cells to produce functional intracellular or secreted proteins, addressing metabolic deficiencies such as propionic acidemia and methylmalonic acidemia.
- Autoimmune and Cardiovascular Therapeutics: Clinical research into localized and systemic mRNA formulations designed to express therapeutic proteins, promote angiogenesis, or modulate immune pathways in heart failure, ischemic heart disease, and autoimmune conditions.
- Manufacturing Facilities: Operation of specialized biomanufacturing plants and technological hubs, including facilities in Norwood, Massachusetts, dedicated to clinical supply production, lipid nanoparticle formulation, and large-scale commercial drug substance manufacturing.
equipe executiva do Moderna
- Stéphane BancelCEO & Director
- Stephen HogePresident
- James M. MockChief Financial Officer
- Shannon Thyme KlingerChief Legal Officer & Corporate Secretary
- Juan AndresChief Operating Officer
- Lavina TalukdarSenior VP & Head of Investor Relations
- Chris RidleyVP & Global Head of Communications
- Tracey FranklinChief People & Digital Technology Officer
- Charbel HaberSenior VP & Head of Global Regulatory Science
- Patrick Norman BergstedtSenior Vice President of Commercial Vaccines
Últimas notícias sobre a Moderna
Moderna returns to profit as Q3 revenue rises 29%
United StatesModerna rises 2.2% on Nasdaq-100 inclusion
United StatesMerck and Moderna melanoma therapy meets Phase 3 goals
United StatesModerna receives FDA approval for mFLUSIVA flu vaccine
United StatesModerna sales total $145M as biotech firm reports Q2 results
United StatesModerna advances mRNA-4200 cancer therapy clinical trial
United States
Comunicados recentes
O que a Moderna (MRNA) comunicou ao mercado, do mais recente para o mais antigo.
Principais indicadores financeiros
Resultados divulgados pela Moderna, em USD.
- Cap. de mercado
- 93,6 bi
- Receita (TTM)
- 2,5 bi
- P/L
- —
- LPA (diluído, TTM)
- -6.5
- Dividend yield
- —
- Margem de lucro
- -110.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,9 bi | -3,1 bi | -2,8 bi | |
| 3,2 bi | -3,9 bi | -3,6 bi | |
| 6,8 bi | -4,2 bi | -4,7 bi | |
| 18,9 bi | 9,4 bi | 8,4 bi |